Market Movers (8-K)
See all →NASDAQ
bioAffinity Technologies stockholders approved a significant reduction in authorized common stock and authorized the issuance of shares related to warrant exercises.
Capital raise
NASDAQ
bioAffinity Technologies released a newsletter detailing commercial expansion of its CyPath Lung test, progress in federal healthcare partnerships, and advancements in its asthma/COPD diagnostic and siRNA therapeutic programs.
Capital raise
NASDAQ
bioAffinity Technologies announced a record number of CyPath Lung tests performed in October 2026, marking the highest monthly testing volume for its noninvasive lung cancer test.
NASDAQ
BioAffinity Technologies announced a 79% year-to-date increase in CyPath Lung testing revenue and doubled unit sales, alongside progress in its precision medicine pipeline.
Capital raise
NASDAQ
bioAffinity Technologies will participate in the Lung Cancer Initiative of North Carolina's Battle of the Blues event to highlight advancements in early lung cancer detection and therapies.
NASDAQ
bioAffinity Technologies announced it will sponsor a presentation at CHEST 2026 to discuss the evolving role of its CyPath Lung test in lung cancer risk stratification and pulmonary nodule management.
Quarterly Earnings (10-Q)
See all →NASDAQ
bioAffinity Technologies reported a net loss of $5.3 million for Q3 2026, with ongoing concerns about its ability to continue as a going concern, despite a 79% increase in CyPath Lung testing revenue.
Capital raise
Worse than expected
NASDAQ
bioAffinity Technologies reports increased revenue for its CyPath Lung diagnostic test but faces substantial doubt about its going concern status and a Nasdaq delisting warning.
Worse than expected
Capital raise
NASDAQ
BioAffinity Technologies reported a widened net loss of $5.1 million in Q3 2025, despite an 86% increase in CyPath Lung revenue, as it navigates strategic shifts and capital raises.
Worse than expected
Capital raise
NASDAQ
BioAffinity Technologies reports increased net losses and significant liquidity challenges, raising substantial doubt about its ability to continue as a going concern, despite growth in its CyPath Lung diagnostic test revenue and new patent grants.
Capital raise
Worse than expected
NASDAQ
bioAffinity Technologies' Q1 2025 revenue decreased by 23% due to strategic actions, but CyPath Lung testing revenue increased significantly.
Worse than expected
Capital raise
NASDAQ
bioAffinity Technologies saw a significant increase in revenue in Q3 2024, primarily due to the acquisition of a clinical pathology lab, but continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Annual Reports (10-K)
NASDAQ
bioAffinity Technologies reported a 34% consolidated revenue decrease to $6.2 million in 2025, driven by strategic divestitures, while its CyPath Lung diagnostic revenue surged 87% and the company raised $16.9 million in equity.
Delay expected
Worse than expected
Capital raise
NASDAQ
bioAffinity Technologies files an amendment to its annual report on Form 10-K to include information required by Part III regarding directors, executive officers, and corporate governance.
NASDAQ
10-K: bioAffinity Technologies Reports Increased Revenue, Outlines Strategic Actions in Annual 10-K Filing
bioAffinity Technologies' 10-K filing reveals a 270% revenue increase driven by the PPLS acquisition, alongside strategic cost-saving measures and continued focus on CyPath Lung commercial growth.
Worse than expected
Capital raise
NASDAQ
10-K: BioAffinity Technologies Details Registered Securities and Corporate Governance in 10-K Filing
BioAffinity Technologies outlines the terms of its common stock and tradeable warrants, along with corporate governance and risk factors, in its annual 10-K filing.
Insider Trading (Form 4)
See all →NASDAQ
Xavier Trinidad Reveles, COO of bioAffinity Technologies, reports acquisition and disposal of common stock on January 10, 2025.
NASDAQ
Executive Chairman Steven Girgenti reports acquisition and disposal of bioAffinity Technologies stock, including a grant of restricted shares and shares held by a trust.
NASDAQ
Maria Zannes, President & CEO of bioAffinity Technologies, reports the acquisition of 37,037 shares of restricted common stock.
NASDAQ
James Michael Edwards, VP and CFO of bioAffinity Technologies, reports the acquisition of 6,172 shares of common stock through a grant and the resulting adjusted beneficial ownership.
NASDAQ
Timothy P. Zannes, Secretary, EVP, and General Counsel of bioAffinity Technologies, acquired 8,641 shares of common stock through a grant, increasing his holdings to 54,765 shares.
NASDAQ
James Michael Edwards, VP and CFO of bioAffinity Technologies, acquired 100,000 shares of common stock on November 5, 2024, through a grant of restricted shares.
Proxy Statements (Def-14A)
See all →NASDAQ
bioAffinity Technologies is convening a Special Meeting of Stockholders on November 20, 2026, to vote on several proposals, including warrant exercises, potential future offerings, and a reduction in authorized shares.
Capital raise
NASDAQ
BioAffinity Technologies, Inc. calls for its Annual Meeting to approve a reverse stock split, significant equity plan expansion, and authorization for future dilutive capital raises.
Capital raise
NASDAQ
BioAffinity Technologies, Inc. issued a supplement to its proxy statement to correct a clerical error in the number of outstanding common shares for its upcoming Special Meeting.
NASDAQ
bioAffinity Technologies calls a Special Meeting to approve significant share issuances, anti-dilution adjustments, and a large equity plan increase, signaling substantial future dilution.
Capital raise
Worse than expected
NASDAQ
bioAffinity Technologies, Inc. has filed a Definitive Proxy Statement (Schedule 14A) with the U.S. Securities and Exchange Commission.
NASDAQ
bioAffinity Technologies, a developer of noninvasive lung cancer diagnostics, is calling an Annual Meeting on July 25, 2025, to seek shareholder approval for a reverse stock split, a substantial increase in authorized shares, and the issuance of millions of shares from warrant exercises, primarily to address Nasdaq listing compliance and facilitate future capital raising.
Capital raise
New Public Companies (S-1)
See all →NASDAQ
bioAffinity Technologies, Inc. has filed an S-1 registration statement to allow selling stockholders to resell up to 999,673 shares of common stock, primarily issuable upon exercise of warrants.
NASDAQ
BioAffinity Technologies, Inc. has filed details regarding its Pre-funded Common Stock Purchase Warrant, outlining terms for exercise, pricing, and potential adjustments.
NASDAQ
bioAffinity Technologies, Inc. has filed a registration statement for a public offering of common stock and pre-funded warrants to raise approximately $4 million for working capital.
Capital raise
NASDAQ
bioAffinity Technologies has filed a registration statement for the resale of up to 497,483 shares of common stock issuable upon the exercise of warrants and conversion of Series B preferred stock.
Capital raise
NASDAQ
bioAffinity Technologies, Inc. is offering up to 729,927 shares of common stock and pre-funded warrants in a best efforts public offering to raise approximately $3.4 million, while facing Nasdaq delisting threats.
Worse than expected
Capital raise
Delay expected
NASDAQ
BioAffinity Technologies, Inc. announced a public offering of common stock and warrants to raise capital, following a reverse stock split and ongoing Nasdaq compliance challenges.
Delay expected
Worse than expected
Capital raise
Schedule 13G - Passive Investments
NASDAQ
HRT Financial LP has disclosed beneficial ownership of 10.9% of bioAffinity Technologies' common stock as of September 30, 2026.
NASDAQ
A group of investment entities led by Michael Bigger reported a complete divestment of their beneficial ownership in bioAffinity Technologies, Inc. common stock, falling below the 5% threshold.
Worse than expected
NASDAQ
Richard K. Crumly, along with ADAMAS LLC and BMUS PARTNERS LLC, has filed a Schedule 13G disclosing a collective beneficial ownership of 11.2% of bioAffinity Technologies, Inc.'s common stock.